Compound Planning Inc. Has $8.14 Million Stake in Johnson & Johnson $JNJ

Key Points

• Compound Planning Inc. has increased its stake in Johnson & Johnson by 21.9%, owning 49,109 shares valued at $8.14 million as of its latest SEC filing.
• Johnson & Johnson reported earnings of $2.77 per share for the latest quarter, exceeding analyst expectations of $2.68, with a revenue increase of 5.8% year-over-year.
• The company plans to pay a quarterly dividend of $1.30 per share on September 9th, 2023, representing an annualized dividend yield of 2.9%.

Compound Planning Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 21.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,109 shares of the company's stock after purchasing an additional 8,832 shares during the period. Compound Planning Inc.'s holdings in Johnson & Johnson were worth $8,144,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Highline Wealth Partners LLC increased its holdings in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the first quarter worth approximately $47,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson in the first quarter worth approximately $49,000. Capital A Wealth Management LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $50,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the first quarter valued at approximately $52,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.0%

Shares of NYSE JNJ opened at $178.8990 on Friday. The stock has a market cap of $430.85 billion, a PE ratio of 19.13, a PEG ratio of 2.28 and a beta of 0.41. The business has a fifty day moving average of $163.04 and a two-hundred day moving average of $159.05. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $180.61. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the previous year, the business posted $2.82 earnings per share. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Analysts Set New Price Targets

Several brokerages have commented on JNJ. UBS Group increased their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Finally, Bank of America increased their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.